by
Strategic Valuation
Language: English
Release Date: November 17, 2017
Exact Sciences Corporation (EXAS) is a publicly traded molecular diagnostics company focused on the early detection and prevention of colon cancer. EXAS has developed, and currently commercializes the Cologuard test, a non-invasive stool-based deoxyribonucleic acid screening test designed to detect...